Focused On-demand Library for Leukotriene A-4 hydrolase

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.







Alternative names:

Leukotriene A(4) hydrolase; Tripeptide aminopeptidase LTA4H

Alternative UPACC:

P09960; B4DNQ9; F8VV40; Q6IAT6; Q9UCT7


Leukotriene A-4 hydrolase, also known as LTA4H, is a bifunctional zinc metalloenzyme with both epoxide hydrolase and aminopeptidase activities. It plays a crucial role in the conversion of LTA4 to leukotriene B4, a pro-inflammatory mediator, and inactivates the neutrophil attractant PGP, a bioactive fragment of collagen, through its aminopeptidase activity. Additionally, LTA4H is involved in the biosynthesis of anti-inflammatory lipid mediators, resolvin E1 and 18S-resolvin E1.

Therapeutic significance:

Understanding the role of Leukotriene A-4 hydrolase could open doors to potential therapeutic strategies, particularly in controlling inflammation and resolving inflammatory conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.